New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
OverviewChart

Quote Panel

Shape
Updated April 27, 2025
1W 0.80 % 1M -18.97 % 3M -81.87 % 1Y -94.41 %

Key Metrics

Shape

  • Market Cap

    749944

  • Shares Outstanding

    3.15M

  • Share in Float

    2.80M

  • Dividende

    0

  • Earning Date

    13 May 2025

  • Price Target

    0.2381

  • Average Volume

    77405

  • Beta

    0.097

  • Range

    0.2255-5.97

  • Industry

    Biotechnology

  • Website

    https://www.avenuetx.com

  • Sector

    Healthcare

Fundamentals

Shape

Relative Strength

Shape

ATXI

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$259M

ShapeNaN%

2025-Revenue

$1.96

ShapeNaN%

2025-EPS

0

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Shape

Buy

Price Target

0.00(-100.00%)

Number of analyst

0

Last analyst upgrade/downgrade

No Data Available

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-33.83
vs -56.36

Q4.22

arrow
arrow

+12423%

92.48
vs -0.75

Q1.23

arrow
arrow

N/A

-103.01
vs -2.04

Q2.23

arrow
arrow

N/A

-39.10
vs -33.82

Q3.23

arrow
arrow

+113%

4.51
vs -33.83

Q4.23

arrow
arrow

-54%

42.11
vs 92.48

Q1.24

arrow
arrow

N/A

-15.40
vs -103.01

Q2.24

arrow
arrow

N/A

-6.43
vs -39.10

Q3.24

arrow
arrow

N/A

-1.92
vs 4.51

Q4.24

arrow
arrow

N/A

-0.22
vs 42.11

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

NA

NA  vs NA

Q4.22

arrow
arrow

NA

NA  vs NA

Q1.23

arrow
arrow

NA

NA  vs NA

Q2.23

arrow
arrow

NA

NA  vs NA

Q3.23

arrow
arrow

NA

NA  vs NA

Q4.23

arrow
arrow

NA

NA  vs NA

Q1.24

arrow
arrow

NA

NA  vs NA

Q2.24

arrow
arrow

NA

NA  vs NA

Q3.24

arrow
arrow

NA

NA  vs NA

Q4.24

arrow
arrow

NA

NA  vs NA

Return on EquityShape

status-upQoQ

Q1.23

arrow
arrow

+600%

6
vs 1.28

Q2.23

arrow
arrow

+75%

0.75
vs 6

Q3.23

arrow
arrow

-14%

-0.14
vs 0.75

Q4.23

arrow
arrow

+40%

0.4
vs -0.14

Q1.24

arrow
arrow

-153%

-1.53
vs 0.4

Q2.24

arrow
arrow

-151%

-1.51
vs -1.53

Q3.24

arrow
arrow

-118%

-1.18
vs -1.51

Q4.24

arrow
arrow

-55%

-0.55
vs -1.18

Institutionnal OwnershipShape

status-upQoQ

Q1.21

arrow
arrow

34

34
vs 35

-3%

Q2.21

arrow
arrow

25

25
vs 34

-26%

Q3.21

arrow
arrow

18

18
vs 25

-28%

Q4.21

arrow
arrow

15

15
vs 18

-17%

Q1.22

arrow
arrow

14

14
vs 15

-7%

Q2.22

arrow
arrow

16

16
vs 14

14%

Q1.23

arrow
arrow

1

1
vs NA

NA

Q2.23

arrow
arrow

1

1
vs 1

NA

Earnings Growth

Latest News

ATXI

globenewswire.com

8 hours ago

Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit
ATXI

globenewswire.com

8 hours ago

Avenue Therapeutics to Participate in Upcoming Investor Conferences
ATXI

globenewswire.com

8 hours ago

Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
ATXI

globenewswire.com

8 hours ago

Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
ATXI

globenewswire.com

16 hours ago

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
ATXI

globenewswire.com

16 hours ago

Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights